VGF — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL29358745	1.00	2/20
SCHEMBL29380618	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL24532058	0.83	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL24532062	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20

Clinical trials — most relevant to VGF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder	PHASE4	COMPLETED
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression	PHASE4	UNKNOWN
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis	PHASE2/PHASE3	NOT_YET_RECRUITING
Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia	PHASE3	COMPLETED
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease	PHASE2	COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Acamprosate to Reduce Symptoms of Alcohol Withdrawal	PHASE2	COMPLETED
Examination of a Soy-Based Supplement for Major Depression	PHASE2	COMPLETED
Efficacy of OnabotulinumtoxinA in Migraine	PHASE2	COMPLETED
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia	PHASE2	COMPLETED
Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues	EARLY_PHASE1	NOT_YET_RECRUITING
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke	nan	UNKNOWN
Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training for Incomplete Spinal Cord Injury Patients	nan	COMPLETED
Non-Invasive Bioelectronic Analytics	nan	ENROLLING_BY_INVITATION
Direct and Cross Effects of Adaptation to Systemic Hyperthermia: Impact on Quality of Life, Neurohormonal and Psychophysiological Human Status	nan	COMPLETED
Effect of Enteral Bovine Lactoferrin in Preterm Infants	nan	COMPLETED
Inflammatory Markers Identification in Migraine Patients	nan	UNKNOWN
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease	nan	ENROLLING_BY_INVITATION
Effects of Genetic Variation on the Efficacy of Aerobic Exercise	nan	COMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Relative Contribution of Brain Insulin Action for Postprandial Metabolism	nan	ACTIVE_NOT_RECRUITING
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)	nan	UNKNOWN
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder	nan	UNKNOWN
Whole Coffee Fruit Concentrate Pilot Study 1	nan	COMPLETED
Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a VGF binder may also engage these)

Protein	Name	Similarity
P20156	—	1.000	P20156 →
P86435	—	1.000	P86435 →
Q0VGU4	—	1.000	Q0VGU4 →
Q9XS63	—	0.991	Q9XS63 →
P26339	—	0.990	P26339 →
Q9QXV0	—	0.988	Q9QXV0 →
P05059	—	0.988	P05059 →
P04404	—	0.987	P04404 →
Q9QXU9	—	0.985	Q9QXU9 →
I3L3R5	—	0.985	I3L3R5 →
Q9GLG4	—	0.983	Q9GLG4 →
Q9UHG2	—	0.982	Q9UHG2 →
Q9Y4B5	—	0.982	Q9Y4B5 →
Q6R6L0	—	0.982	Q6R6L0 →
P10354	—	0.981	P10354 →
P05060	—	0.981	P05060 →
Q3TVI8	—	0.980	Q3TVI8 →
P23389	—	0.980	P23389 →
A2VD12	—	0.979	A2VD12 →
Q96AQ6	—	0.979	Q96AQ6 →
P20800	—	0.979	P20800 →
Q765Z5	—	0.979	Q765Z5 →
Q9P1Y5	—	0.979	Q9P1Y5 →
P10645	—	0.978	P10645 →
P13207	—	0.978	P13207 →
P23943	—	0.978	P23943 →
Q3KP66	—	0.978	Q3KP66 →
Q5NRQ0	—	0.978	Q5NRQ0 →
Q95MI6	—	0.977	Q95MI6 →
Q1RMJ9	—	0.977	Q1RMJ9 →